Isabelle Lochon

794 total citations
22 papers, 574 citations indexed

About

Isabelle Lochon is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Isabelle Lochon has authored 22 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Isabelle Lochon's work include Cancer Treatment and Pharmacology (8 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Research Studies (5 papers). Isabelle Lochon is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Cancer therapeutics and mechanisms (7 papers) and Lung Cancer Research Studies (5 papers). Isabelle Lochon collaborates with scholars based in France and United States. Isabelle Lochon's co-authors include Étienne Chatelut, Pierre Canal, R. Bugat, Sylvie M. Guichard, Isabelle Hennebelle, C. Terret, Janick Sèlves, P Chevreau, Mondher Mahjoubi and Brigitte Tranchand and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

Isabelle Lochon

22 papers receiving 555 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabelle Lochon France 13 326 248 119 69 51 22 574
Ger‐Jan Sanderink France 10 348 1.1× 189 0.8× 94 0.8× 22 0.3× 36 0.7× 12 712
E. Boven Netherlands 11 503 1.5× 308 1.2× 66 0.6× 54 0.8× 57 1.1× 25 770
S. Matthews United States 14 288 0.9× 276 1.1× 77 0.6× 49 0.7× 39 0.8× 41 747
Chan Kk Malaysia 13 162 0.5× 169 0.7× 126 1.1× 60 0.9× 38 0.7× 26 576
Femke M. de Man Netherlands 10 245 0.8× 219 0.9× 77 0.6× 24 0.3× 47 0.9× 19 539
Marius Dohse Germany 9 497 1.5× 230 0.9× 103 0.9× 25 0.4× 40 0.8× 13 788
Tingting Liu China 16 361 1.1× 255 1.0× 60 0.5× 54 0.8× 30 0.6× 77 770
Firas Baidoun United States 6 311 1.0× 246 1.0× 132 1.1× 105 1.5× 13 0.3× 28 722
Maura A. Kraynak United States 13 431 1.3× 308 1.2× 77 0.6× 24 0.3× 28 0.5× 19 807

Countries citing papers authored by Isabelle Lochon

Since Specialization
Citations

This map shows the geographic impact of Isabelle Lochon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Lochon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Lochon more than expected).

Fields of papers citing papers by Isabelle Lochon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Lochon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Lochon. The network helps show where Isabelle Lochon may publish in the future.

Co-authorship network of co-authors of Isabelle Lochon

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Lochon. A scholar is included among the top collaborators of Isabelle Lochon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Lochon. Isabelle Lochon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Fabienne, Sophie Broutin, Jérôme Guitton, et al.. (2017). Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study.. Journal of Clinical Oncology. 35(15_suppl). 4554–4554. 1 indexed citations
2.
Thomas, Fabienne, Isabelle Hennebelle, Caroline Delmas, et al.. (2015). Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clinical Pharmacology & Therapeutics. 99(2). 235–242. 31 indexed citations
3.
4.
Gandia, Peggy, Cécile Arellano, Isabelle Lochon, et al.. (2011). Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer. Current Clinical Pharmacology. 6(4). 274–279. 3 indexed citations
5.
Ferron, Gwénaël, Laurence Gladieff, Jean‐Pierre Delord, et al.. (2007). Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemotherapy and Pharmacology. 62(4). 679–683. 30 indexed citations
6.
Delord, Jean Pierre, Florence Dalenc, Frédéric Pinguet, et al.. (2007). A Phase I Dose-Escalating and Pharmacokinetic Study of Docetaxel and Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. Oncology. 72(5-6). 322–325. 3 indexed citations
7.
Puisset, Florent, Étienne Chatelut, Alex Sparreboom, et al.. (2006). Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemotherapy and Pharmacology. 60(2). 305–308. 11 indexed citations
8.
Delord, Jean‐Pierre, Jean‐Yves Pierga, Véronique Dièras, et al.. (2005). A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. British Journal of Cancer. 92(5). 820–826. 21 indexed citations
9.
Puisset, Florent, Florence Dalenc, Étienne Chatelut, et al.. (2005). Dexamethasone as a probe for vinorelbine clearance. British Journal of Clinical Pharmacology. 60(1). 45–53. 12 indexed citations
10.
Urien, Saı̈k, et al.. (2004). Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemotherapy and Pharmacology. 55(1). 55–60. 51 indexed citations
11.
Léger, F., Sophie Séronie-Vivien, Isabelle Lochon, et al.. (2002). Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing. European Journal of Cancer. 38(1). 52–56. 24 indexed citations
12.
Guimbaud, Rosine, Sylvie M. Guichard, Viviane Bertrand, et al.. (2000). Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemotherapy and Pharmacology. 45(6). 477–482. 31 indexed citations
13.
Guichard, Sylvie M., C. Terret, Isabelle Hennebelle, et al.. (1999). CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. British Journal of Cancer. 80(3-4). 364–370. 118 indexed citations
14.
Tranchand, Brigitte, Étienne Chatelut, Gilles Freyer, et al.. (1999). A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemotherapy and Pharmacology. 43(4). 316–322. 32 indexed citations
15.
Guichard, Sylvie M., Étienne Chatelut, Isabelle Lochon, et al.. (1998). Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemotherapy and Pharmacology. 42(2). 165–170. 58 indexed citations
16.
Bachaud, Jean‐Marc, M. Murris‐Espin, C. Hermant, et al.. (1998). Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. European Journal of Clinical Pharmacology. 54(9-10). 677–683. 18 indexed citations
17.
18.
Nguyen, Laurent, Étienne Chatelut, Christine Chevreau, et al.. (1997). Population pharmacokinetics of total and unbound etoposide. Cancer Chemotherapy and Pharmacology. 41(2). 125–132. 54 indexed citations
19.
Lafon, Corinne, Isabelle Lochon, A Nehmé, et al.. (1997). Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. British Journal of Cancer. 75(3). 333–340. 29 indexed citations
20.
Chatelut, Étienne, et al.. (1997). [Bayesian estimation of pharmacokinetic parameters of etoposide].. PubMed. 84(7). 699–703. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ger‐Jan Sanderink Breakdown of academic impact, for papers by E. Boven Breakdown of academic impact, for papers by S. Matthews Breakdown of academic impact, for papers by Chan Kk Breakdown of academic impact, for papers by Femke M. de Man Breakdown of academic impact, for papers by Marius Dohse Breakdown of academic impact, for papers by Tingting Liu Breakdown of academic impact, for papers by Firas Baidoun Breakdown of academic impact, for papers by Maura A. Kraynak
Rankless by CCL
2026